In December, we added 106 citations in DIDB, including 56 in vitro (with 22 articles published in December 2024) and 50 in vivo articles (with 41 articles published in December 2024).
3 NDA/BLAs approved in 2024, including revumenib (REVUFORJ), sulopenem and probenecid (ORLYNVAH), and zanidatama (ZIIHERA) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.